- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01695694
Violence and HIV Risk Among Women (VHRW)
HIV Risk Reduction for Women Reporting Intimate Partner Violence
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The two foremost health problems impacting young adult women are STDs/HIV infection and intimate partner violence (IPV). STDs pose a significant public health issue in the US, particularly among women. The consequences of some STDs are more severe for women, and include infertility, pelvic inflammatory disease, and brain, cardiovascular, and organ damage. Women with STDs are at increased risk for HIV. The proportion of AIDS cases among US adult and adolescent women has more than tripled since 1985. Approximately 12,000 US women are infected with HIV annually, primarily through heterosexual contact. Also, in the US HIV is particularly affecting women of color and those in low-income urban areas.
IPV also affects many women. While the causal links between IPV and HIV risk or infection have not yet been established, emerging empirical evidence has drawn connections between IPV with HIV risk. Several researchers have highlighted the importance of developing sexual risk reduction interventions that address the growing concern of gender-based violence against women. Also, scholars are calling for HIV prevention programs aimed at women to be more comprehensive; for example, by combining them with STD screening or with programs designed to reduce violence against women. Despite this call, there are very few empirically tested interventions for prevention and treatment targeting women who are at risk for STDs/HIV and experience IPV in their intimate relationships. To address high risk sexual behaviors among women who experience gender-based violence in their intimate relationships, I have adapted an existing information-motivation-behavioral skills (IMB) STD/HIV prevention intervention for reducing high sexual risk-taking behaviors. The STD/HIV and IPV comprehensive intervention will address both sexual risk reduction and IPV risk; the intention is to help women to acquire knowledge, skills, and strategies that will reduce their risk for both STDs/HIV and IPV.
Aim 1: To assess the feasibility and acceptability of the adapted IMB STD/HIV prevention intervention by implementing the intervention with a sample of women who are at risk for HIV/STDs and experience IPV. To achieve this aim:
- 120 women who are at risk for HIV/STDs and have experienced IPV will be randomized either to receive the experimental prevention intervention or to attend a structurally similar drop-in enhanced support group at a domestic violence agency.
- Enrollment, attendance, and attrition data will be used to determine the feasibility of the intervention.
- The acceptability of the intervention will be appraised by analyzing pre- and post-intervention acceptability ratings completed by subjects and interventionists.
Aim 2: To gather preliminary evidence of the efficacy of the theoretically guided intervention using a controlled design. To achieve this aim:
- Women in the experimental and control groups will be assessed at baseline, post-intervention, and at a 3-month follow-up.
- Outcome analyses to calculate effect sizes for use in future power analyses for a larger RCT of the proposed intervention will include measures on primary variables of hypothesized risk antecedents, standard measures of protected and unprotected sex, and secondary variables such as mental health, self esteem, and IPV experiences.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
New York
-
Rochester, New York, Forenede Stater, 14642
- University of Rochester
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Women will be eligible to participate in the research study if they meet the following criteria:
- between ages 18 and 49;
- heterosexually active;
- have experienced intimate partner violence in the last three months;
- have engaged in risky sexual behavior in the past three months;
- not currently pregnant or trying to become pregnant; and
- physically and psychologically capable of providing informed consent. All subjects will be required to provide written informed consent prior to enrolling in the study.
Exclusion Criteria:
Persons who meet one or more of the following criteria will be excluded from the study:
- men;
- women who have active psychosis or impaired mental status (confirmed with a Mini-Mental Status Exam);
- are unable to understand spoken English;
- are less than 18 years old or greater than 49 years old;
- are currently pregnant or trying to become pregnant
- women who are exclusively in same-sex relationships.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: community support group
|
|
Eksperimentel: supporting positive and healthy relationships
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change from Baseline in sexual risk behavior at 3 months
Tidsramme: at the completion of 3 months after the intervention
|
Sexual risk behavior is assessed by self-reported number sexual partners in the last three months and number of episodes of unprotected sex with each partner
|
at the completion of 3 months after the intervention
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change from Baseline in experience of violence at 3 months
Tidsramme: At the end 3-months after the end of the intervention
|
Participant's experiences of violence as well as the frequency and intensity of thse experiences will be assessed using established measures of intimate partner violence
|
At the end 3-months after the end of the intervention
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Mona Mittal, PhD, University of Rochester
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- RSRB00040309
- 7K01MH080660 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV-risikoreduktion
-
Kafrelsheikh UniversityUkendtAt sammenligne komplikationer af begge teknikker i Wise Pattern Reduction Mammaplasty og at korrelere mellem komplikationer og patientmedierede faktorerEgypten
-
Pakistan Institute of Living and LearningAfsluttetPsykose | At Risk Mental State (ARMS)Pakistan
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)AfsluttetFørste episode psykose (FEP) | At Risk Mental State (ARMS)Forenede Stater
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutteringHIV | HIV-testning | HIV-kobling til pleje | HIV behandlingForenede Stater
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationAfsluttetPartner HIV-testning | Par HIV Rådgivning | Parkommunikation | HIV-forekomstCameroun, Dominikanske republik, Georgien, Indien
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement og andre samarbejdspartnereUkendtHIV | HIV-uinficerede børn | Børn udsat for HIVCameroun
-
University of MinnesotaTrukket tilbageHIV-infektioner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS og infektionerForenede Stater
-
CDC FoundationGilead SciencesUkendtHIV præeksponeringsprofylakse | HIV KemoprofylakseForenede Stater
-
Erasmus Medical CenterIkke rekrutterer endnuHIV-infektioner | Hiv | HIV-1-infektion | HIV I infektionHolland
-
Hospital Clinic of BarcelonaAfsluttetIntegrasehæmmere, HIV; HIV PROTEASE HÆMMERSpanien
Kliniske forsøg med community support group
-
Stanford UniversityCalifornia Initiative to Advance Precision Medicine; Pacific Cancer Care; The Latino Cancer Institute og andre samarbejdspartnereAfsluttet
-
Tulane University School of Social WorkUnited States Agency for International Development (USAID)Afsluttet
-
Women's College HospitalUniversity Health Network, Toronto; Memorial Sloan Kettering Cancer Center og andre samarbejdspartnereAfsluttetUterine cervikale neoplasmer | Uterine neoplasmer | Genitale neoplasmer, kvindelige | Ovariale neoplasmer | Seksuelle dysfunktioner, psykologiskeCanada, Forenede Stater
-
Weill Medical College of Cornell UniversityRekruttering
-
University of Texas at AustinIkke rekrutterer endnuKroniske nyresygdomme | NYRESSÆTTE, KRONISK
-
University of Central FloridaAlzheimer's and Dementia Resource CenterAfsluttetDemens | Alzheimers sygdomForenede Stater
-
Foundation for Professional Development (Pty) LtdNational Institute of Mental Health (NIMH); National Institutes of Health... og andre samarbejdspartnereAktiv, ikke rekrutterendeForbered | HIV-forebyggelse | Omkostningseffektivitet | UngdomSydafrika
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteAfsluttet
-
Rhode Island HospitalAktiv, ikke rekrutterendeMyokardieinfarkt | Lungebetændelse | Hospital Genindlæggelse | KOL
-
NYU Langone HealthAgency for Healthcare Research and Quality (AHRQ)Ikke rekrutterer endnuType 2 diabetesForenede Stater